Table 3 Change in VACS index between baseline and 18 months by randomization group and cumulative adherence (high versus low) under different methods assumptions. ZINC trial 2013–2015

Per-protocol effect—main analysis^a

−8.01 (− 16.42, 0.01)

Per-protocol effect—high adherence ≥70%^a

−4.07 (− 11.50, 2.75)

Per-protocol effect—high adherence ≥90%^a

− 12.34 (− 12.14, − 4.14)

Per-protocol effect—high adherence ≥80%—riboflavin test^a

−3.48 (− 10.44, 4.27)

Per-protocol—change in the temporal order of post-baseline covariates^a

− 7.63 (− 15.21, 0.39)

Intention-to-treat with inverse probability of censoring weights^a

−7.08 (− 13.98, 0.04)

Intention-to-treat—original analysis with multiple [4] imputation

− 4.68 (− 9.62, 0.25)

Per-protocol—original “standard” analysis [4]

−7.49 (− 13.74, − 1.23)